Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Carlo Fremd"'
Autor:
Dirk Jäger, Aileen Berger, Alexandra Tuch, Claudia Luckner‐Minden, Rosa Eurich, Mario Hlevnjak, Andreas Schneeweiss, Peter Lichter, Sebastian Aulmann, Claus‐Peter Heussel, Carlo Fremd, Richard Harbottle, Inka Zörnig, Patrick Schmidt
Publikováno v:
Clinical and Translational Medicine, Vol 14, Iss 7, Pp n/a-n/a (2024)
Externí odkaz:
https://doaj.org/article/d760168d1320416e85cdc19cb58e2a0d
Autor:
Line Hoeltgen MD, Eva Meixner MD, Philipp Hoegen MD, Elisabetta Sandrini MD, Fabian Weykamp MD, Tobias Forster MD, Maria Vinsensia MD, Kristin Lang MD, Laila König MD, Nathalie Arians MD, Carlo Fremd MD, Laura L. Michel MD, Katharina Smetanay MD, Andreas Schneeweiss MD, Markus Wallwiener MD, Jürgen Debus MD, PhD, Juliane Hörner-Rieber MD
Publikováno v:
Technology in Cancer Research & Treatment, Vol 22 (2023)
Objective: Women with locally advanced breast cancer (LABC) or inoperable local recurrence often suffer from a significantly reduced quality of life (QOL) due to local tumor-associated pain, bleeding, exulceration, or malodorous discharge. We aimed t
Externí odkaz:
https://doaj.org/article/c06b98b514704b71a02c3567217cf054
Publikováno v:
Pathogens, Vol 12, Iss 12, p 1387 (2023)
Based on epidemiological evidence and molecular findings, a possible association of Epstein–Barr virus (EBV) with the carcinogenesis of breast cancer has been described. However, the frequency of EBV in breast cancer and the role of EBV regarding t
Externí odkaz:
https://doaj.org/article/081ec844e506497f8f597c9139c63164
Autor:
Eva Meixner MD, Line Hoeltgen MD, Philipp Hoegen MD, Laila König MD, Nathalie Arians MD, Laura L. Michel MD, Katharina Smetanay MD, Carlo Fremd MD, Andreas Schneeweiss MD, Jürgen Debus MD, PhD, Juliane Hörner-Rieber MD
Publikováno v:
Technology in Cancer Research & Treatment, Vol 21 (2022)
Introduction: In the adjuvant setting for cervical cancer, classical risk factors for postoperative radiochemotherapy have been established. However, data on laboratory changes during therapy and the prognostic value of serological markers are limite
Externí odkaz:
https://doaj.org/article/2d3fcd632edf4475ac677ed78770906a
Autor:
Thomas M Deutsch, Michelle Kobel, Manuel Feisst, Fabian Riedel, Katharina Smetanay, Carlo Fremd, Laura Michel, Michael Golatta, Joerg Heil, Markus Wallwiener, Andreas Schneeweiss
Publikováno v:
Cancer Research. 82:P2-12
Background: Pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT) is associated with beneficial long-term outcome in early breast cancer (EBC). pCR is defined as ypT0/is, ypN0. It is well known that pCR rates depend on tumor subtyp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd9437379f1038018561741cdc42dfa5
https://doi.org/10.1158/1538-7445.sabcs21-p2-12-08
https://doi.org/10.1158/1538-7445.sabcs21-p2-12-08
Autor:
Stefanie Fischer, Thorsten O. Götze, Aurelius Omlin, Richard D. Baird, Keith M. Dawson, Christof Zitt, Zita Arany, Gaby Tresch, Ulrike Fiedler, Simone Jeger, Samson Fung, Philippe Legenne, Nicolas Leupin, Andreas Schneeweiss, Carlo Fremd
Publikováno v:
JCO precision oncology. 6
The human epidermal growth factor receptor 2 (HER2, ERBB2) is amplified or overexpressed in approximately 20% of breast cancers. HER2 amplification results in increased homodimerization and HER3 heterodimerization, with HER2/HER3 heterodimers promoti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::850df9d50295b764da0da0e6aaa4af7b
https://pubmed.ncbi.nlm.nih.gov/36331248
https://pubmed.ncbi.nlm.nih.gov/36331248
Autor:
Juliane Nees, TM Deutsch, Sabine Riethdorf, Klaus Pantel, Manuel Feisst, Florian Schütz, Andreas D. Hartkopf, Markus Wallwiener, Chiara Fischer, Andreas Trumpp, Carlo Fremd, Andreas Schneeweiss
Publikováno v:
Breast Cancer Research and Treatment
Purpose As an independent, negative-prognostic biomarker for progression-free survival (PFS) and overall survival (OS), circulating tumor cells (CTCs) constitute a promising component for developing a liquid biopsy for patients with metastatic breast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96e3cce719b51bd28af8db7394faf080
http://europepmc.org/articles/PMC7274999
http://europepmc.org/articles/PMC7274999
Publikováno v:
Future Oncology. 16:4439-4453
Since the US FDA-approval of the first immune checkpoint inhibitor, anticytotoxic T-lymphocyte antigen-4 monoclonal antibody ipilimumab, for metastatic melanoma on 28 March 2011, another six agents have been granted use among a multitude of tumors, i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63671f82e5d5ec3aa0b7a359767c496b
https://doi.org/10.2217/fon-2019-0468
https://doi.org/10.2217/fon-2019-0468
Autor:
Thomas, Walle, Sunanjay, Bajaj, Joscha A, Kraske, Thomas, Rösner, Christiane S, Cussigh, Katharina A, Kälber, Lisa Jasmin, Müller, Sophia Boyoung, Strobel, Jana, Burghaus, Stefan M, Kallenberger, Christoph K, Stein-Thöringer, Maximilian, Jenzer, Antonia, Schubert, Steffen, Kahle, Anja, Williams, Birgit, Hoyler, Lin, Zielske, Renate, Skatula, Stefanie, Sawall, Mathias F, Leber, Russell Z, Kunes, Johannes, Krisam, Carlo, Fremd, Andreas, Schneeweiss, Jürgen, Krauss, Leonidas, Apostolidis, Anne Katrin, Berger, Georg M, Haag, Stefanie, Zschäbitz, Niels, Halama, Christoph, Springfeld, Romy, Kirsten, Jessica C, Hassel, Dirk, Jäger
Publikováno v:
Nature cancer. 3(9)
Patients with cancer frequently receive immune-checkpoint inhibitors (ICIs), which may modulate immune responses to COVID-19 vaccines. Recently, cytokine release syndrome (CRS) was observed in a patient with cancer who received BTN162b2 vaccination u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ac6ccdd33c3a8274685ff77e96cbeb48
https://pubmed.ncbi.nlm.nih.gov/35840692
https://pubmed.ncbi.nlm.nih.gov/35840692
Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer
Autor:
Chiara Fischer, Thomas M. Deutsch, Manuel Feisst, Nathalie Rippinger, Fabian Riedel, Andreas D. Hartkopf, Sara Y. Brucker, Christoph Domschke, Carlo Fremd, Laura Michel, Barbara Burwinkel, Andreas Schneeweiss, Andrey Turchinovich, Markus Wallwiener
Publikováno v:
Archives of gynecology and obstetrics. 306(3)
Purpose Circulating miRNAs can provide valid prognostic and predictive information for breast cancer diagnosis and subsequent management. They may comprise quintessential biomarkers that can be obtained minimally invasively from liquid biopsy in meta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c667e4cc6ea1dc96278f9af51104e5df
https://pubmed.ncbi.nlm.nih.gov/35237856
https://pubmed.ncbi.nlm.nih.gov/35237856